ѻý

Dexcom's CGM Interoperability Expands; Warfarin and Osteoporosis; Maine Bans PFAS

<ѻý class="mpt-content-deck">— News and commentary from the endocrinology world
MedpageToday
ENDOBREAK centered between 8 illustrated body organs.

The FDA granted clearance for third-party apps to connect with (CGMs) by integrating real-time CGM data into their digital health apps and devices.

Patients with had a lower risk for death and diabetes-related complications like heart and kidney disease, stroke, eye, and foot complications. "People who adhere to their antidepressants have better diabetes outcomes and quality of life than those with poor adherence," said study author Chi-Shin Wu, MD, PhD, of the National Taiwan University Hospital, in a statement. (Journal of Clinical Endocrinology & Metabolism)

Patients on had a higher risk of osteoporosis and lower bone mineral density, with warfarin being a worse offender than direct-acting oral anticoagulants. (Bone)

Maine passed a first-of-its-kind law banning the use of -- a family of endocrine-disrupting chemicals -- by the year 2030. (The Guardian)

within the first few years of life tended to have slightly higher BMIs in early childhood. (JAMA Network Open)

And in related news, the National Association of Pediatric Nurse Practitioners released a new position statement on how to both prevent and identify . (Journal of Pediatric Health Care)

The International Osteoporosis Foundation paired with the European Renal Association-European Dialysis and Transplant Association to release new clinical practice guidelines with an algorithm for managing patients with . (Osteoporosis International)

The University of South Florida will receive an NIH grant of nearly $70 million to research how and . (Business Observer FL)

  • author['full_name']

    Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.